Science Blog

Science news straight from the source

Navigation

  • Topics
    • Aerospace
    • Animals
    • Anthro and Archaeology
    • Bio and Medicine
    • Brain and Behavior
    • Business and Economy
    • Computers and Electronics
    • Education and Outreach
    • Energy and Environment
    • Geoscience
    • Internet and Communication
    • Media and Entertainment
    • Nanotech, Chem and Materials
    • Physics and Numbers
    • Security and Defense
    • Software
    • Space
    • Transportation
  • Reader Blogs
  • Commerce
  • Register/Login
Home
  • Contact
  • Home
Google

Recent Comments

  • That sounds dangerous
  • On the contrary, that is
  • a little bit of knowledge...
  • Bloody leeches
  • Love Ha see
more

Reader Blogs

  • Extreme Competitive Sports - a Fitness Test for DNA
  • Cure For Cancer, Diabetes, marijuana and cocaine addiction, glucose intolerance, obesity, what more do you want!
  • Global Warming: Increased Public Acceptance May Be Tenuous
  • France: The Creation of New Family Biographies
more

health and medicine stuff

High Levels of Antibodies. Low Levels of Cancer?

Active immunisation can stimulate the body to produce highly efficient IgE antibodies that attack tumours. This breakthrough, achieved in an animal model, is based on the skilful combination of two established experimental methods. The results are now being published in Cancer Research and are part of a project funded by the Austrian Science Fund FWF. The antibodies produced during the project belong to a class that also plays a key role in the development of allergic reactions. Consequently, the results will be a key focal point at the 1st International AllergoOncology Symposium, which is to be held today in Vienna, Austria.

  • Add new comment
  • Read more
  • 290 reads



Largest Job Search Engine In The World

  • Add new comment
  • 667 reads



AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy

VIENNA, Austria and CHAPEL HILL, N.C., US, March 7 -- AOP Orphan Pharmaceuticals AG ("AOP Orphan") and Lantibio, Inc. ("Lantibio") today announced positive final results from their placebo controlled, double-blinded Phase II clinical study of Moli1901, an experimental compound to treat cystic fibrosis ("CF"). Moli1901 is being developed by AOP Orphan in Europe under a licensing and commercialization agreement with Lantibio. The study, performed at multiple centers in Europe, was designed to investigate safety and tolerability of aerosolized Moli1901 in adolescents (12 years of age or older) and adults with CF.

  • Add new comment
  • Read more
  • 436 reads



Incinerators and biosecurity Bird Flu H5N1

Bird flu virus can go undetected for some time in remote areas and smallholdings especially in some Asian countries.

  • Add new comment
  • Read more
  • 515 reads



Great American Sleep Challenge

Get better sleep, improve your life

  • Add new comment
  • Read more
  • 371 reads



HealthGate with EpiCor improves immune function

New Yeast discovery offers hope for immune support in human health.

  • Add new comment
  • Read more
  • 836 reads



Environmental and Geographical Issue and HIV/AIDS in Bangladesh

Environmental and Geographical Issue and HIV/AIDS in Bangladesh

  • Add new comment
  • Read more
  • 1002 reads



DNA as phonons ANTENNA

See in italian APOPTOSIS
http://www.egocreanet.it

  • Add new comment
  • Read more
  • 628 reads



TrueVision Microsocpes

  • Add new comment
  • 710 reads



Need Expert Advice: Endorphins Productions in Human

  • Add new comment
  • 555 reads



12345next ›last »
Google
Copyright, Science Blog.
Think. It's not illegal yet. Read our Privacy Policy.
RoopleTheme